Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: A national survey of urologist beliefs and practices

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 1993-1997

  Wasson, John H ^a   Fowler Jr , Floyd J ^a   Barry, Michael J ^a  

^a NONE

Author keywords

Androgens; Physician's practice patterns; Prostate specific antigen; Prostatic neoplasms; Urology

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; HUMAN; MEDICAL PRACTICE; MEDICARE; NORMAL HUMAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0032413748     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63223-3     Document Type: Article

References (22)

1. Byer, D. P. and Corle, D. K.: Hormone therapy for prostate cancer: results of the Veteran's Administration Cooperative Urological Research Group studies. NCI Monographs 7: 165, 1988.
2. Zincke, H.: Combined surgery and immediate adjuvant hormonal treatment for Stage D1 adenocarcinoma of the prostate: Mayo Clinic experience. Sem. Urol., 8: 175, 1990.
3. deKernion, J. B., Neuwirth, H., Stein, A., Dorey, F., Stenzl, A., Hannah, J. and Blyth, B.: Prognosis of patients with Stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J. Urol., 144: 700, 1990.
4. Kramolowsky E. V.: The value of testosterone deprivation in Stage D1 carcinoma of the prostate. J. Urol., 139: 1242, 1988.
5. Kozlowski, J. M., Ellis, W. J. and Grayhack, J. T.: Advanced prostatic carcinoma: Early versus late endocrine therapy. Urol. Clin. N. Amer., 18: 15, 1991.
6. Shpall, A. I., Dorey, F. and Litwin, M.: Health-related quality of life of men undergoing different treatments for advanced prostate cancer. J. Urol., 157: 333, abstract 1301, 1997.
7. Cox, R. L. and Crawford, E. D.: Estrogens in the treatment of prostate cancer. J. Urol., 154: 1991, 1995.
8. Alivizatos, G. and Oosterhof, G. O. N.: Update of hormonal treatment in cancer of the prostate. Anticancer Drugs, 4: 301, 1993.
9. Klein, E. A.: Hormone therapy for prostate cancer: a topical perspective. Urology, 47: 3, 1996.
10. Denis, L.: Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Prostate, 27: 233, 1995.
11. Schmidt, J. D.: The case for early endocrine treatment of advanced or metastatic prostate cancer. Prostate, 28: 201, 1996.
12. Smith, P. H.: Carcinoma of prostate: case against immediate hormonal therapy. Prostate, 28: 205, 1996.
13. Gee, W. F., Holtgrewe, H. L., Albertsen, P. C., Litwin, M. S., Manyak, M. J., O'Leary, M. P. and Painter, M. R.: Practice trends in the diagnosis and management of prostate cancer in the United States. J. Urol., 154: 207, 1995.
14. Middleton, R. G., Thompson, I. M., Austenfeld, M S., Cooner, W. H, Correa, R. J., Gibbons, R. P., Miller, H. C., Oesterling, J. E., Resnick, M. I., Smalley, S. R. and Wasson, J. H. for the Prostate Cancer Clinical Guidelines Panel: Report on the management of clinically localized prostate cancer. Baltimore: American Urological Association, Inc., 1995.
15. Vogelzang, N. J., Chodak, G. W., Soloway, M. S., Block, N. L., Schellhammer, P. F., Smith, J. A., Caplan, R. J. and Kennealey, G. T. for the Zoladex Prostate Study Group: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology, 46: 220, 1995.
16. Scher, H. I. and Fossa, S.: Prostate cancer in the era of prostate-specific antigen. Curr. Opin. Oncol., 7: 281, 1995.
17. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: the initial results of the Medical Research Council trial. Brit. Med. J., 79: 235, 1997.
18. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3282 deaths in 5710 patients. Lancet, 346: 265, 1995.
19. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Wilding, G. and Blumenstein, B. A.: Comparison of bilateral orchiectomy with or without flutemide for the treatment of patients with stage D2 adenocarcinoma of the prostate: results of NCI Intergroup Study 0105 (SWOG and ECOG). J. Urol., 157: 336, abstract 1311, 1997.
20. 0 Prostatic Carcinoma. Urology, 49: 65, 1997.
21. Health Care Financing Administration: Medicare claims data, calendar year 1995.
22. Cook, D. A., Sinibaldi, V. J. W., Carducci, M. A., Schneyer, C. R., Dobs, A. and Eisenberger, M. A.: Osteopenia in men with prostate cancer treated with androgen deprivation. J. Urol., 157: 232, abstract 906, 1997.